YieldMax MSTR Option Income Strategy ETF vs Pfizer Inc — how do they compare? YieldMax MSTR Option Income Strategy ETF trades at $14.8, while Pfizer Inc trades at $27.9 (market cap $158.39B). The key difference: Pfizer Inc pays a 6.19% dividend while YieldMax MSTR Option Income Strategy ETF pays none, and Pfizer Inc is trading nearer its 52-week high, YieldMax MSTR Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| MSTY | PFE | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $81.00 | $29.02 |
52-Week Low | $11.55 | $23.60 |
Market Cap | — | $158.39B |
Volume | — | 29,869,932 |
Enterprise Value | — | $209.89B |
Dividend Yield | — | 6.19% |
Signals from Pluang's Aura AI — not financial advice
MSTY trades at $15.49, down 3.55% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF generates weekly dividends, with recent payouts ranging from $0.15 to $0.28. News coverage highlights high distribution yields but also significant NAV erosion, with some sources reporting a 67.45% decline over the past year. Support and resistance are tightly clustered around $15-$16, indicating limited near-term price movement.
The outlook is mixed: high income potential from distributions appeals to yield-seeking investors, but structural risks and capital depreciation pose substantial downside. Investors face uncapped losses despite weekly payouts, with fees and tax implications further eroding returns. Careful risk assessment is essential given the fund's volatility and performance history.
Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.
Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.
Trailing returns across standard periods
Latest headlines on both assets
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →